Oracle Investment Management Inc Contrafect Corp Transaction History

Oracle Investment Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$2.79 - $4.45 $41,850 - $66,750	15,000 Added 0.77%	1,969,222 $6.05 Million
Q1 2022 May 16, 2022	BUY	$2.26 - $3.84 $4,067 - $6,912	1,800 Added 0.09%	1,954,222 $7.13 Million
Q4 2021 Feb 14, 2022	BUY	$2.47 - $4.14 $650,894 - $1.09 Million	263,520 Added 15.6%	1,952,422 $5.14 Million
Q2 2021 Aug 16, 2021	BUY	$3.58 - $4.9 $488,594 - $668,747	136,479 Added 8.79%	1,688,902 $7.43 Million
Q1 2021 May 17, 2021	BUY	$4.46 - $6.68 $6.18 Million - $9.25 Million	1,384,836 Added 826.34%	1,552,423 $7.45 Million

Q3 2020 Nov 16, 2020	BUY	$5.05 - $6.99 $195,647 - $270,806	38,742 Added 30.07%	167,587 $885,000
Q1 2020 May 15, 2020	BUY	$5.5 - $12.3 $708,647 - $1.58 Million	128,845 New	128,845 $742,000

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Oracle Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Oracle Investment Management Inc with notifications on news.